Prevalence of cancer therapy cardiotoxicity as assessed by imaging procedures: A scoping review.
cancer therapy
cardiotoxicity
imaging
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
08
03
2023
received:
22
02
2023
accepted:
13
03
2023
medline:
7
6
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
ppublish
Résumé
Advances in treatment and optimization of chemotherapy protocols have greatly improved survival in cancer patients. Unfortunately, treatment can cause a reduction in left ventricular (LV) ejection fraction (EF) leading to cancer therapy-related cardiac dysfunction (CTRCD). We conducted a scoping review of published literature in order to identify and summarize the reported prevalence of cardiotoxicity evaluated by noninvasive imaging procedures in a wide-ranging of patients referred to cancer treatment as chemotherapy and/or radiation therapy. Different databases were checked (PubMed, Embase, and Web of Science) to identify studies published from January 2000 to June 2021. Articles were included if they reported data on LVEF evaluation in oncological patients treated with chemotherapeutic agents and/or radiotherapy, measured by echocardiography and/or nuclear or cardiac magnetic resonance imaging test, providing criteria of CTRCD evaluation such as the specific threshold for LVEF decrease. From 963 citations identified, 46 articles, comprising 6841 patients, met the criteria for the inclusion in the scoping review. The summary prevalence of CTRCD as assessed by imaging procedures in the studies reviewed was 17% (95% confidence interval, 14-20). The results of our scoping review endorse the recommendations regarding imaging modalities to ensure identification of cardiotoxicity in patients undergoing cancer therapies. However, to improve patient management, more homogeneous CTRCD evaluation studies are required, reporting a detailed clinical assessment of the patient before, during and after treatment.
Sections du résumé
BACKGROUND
Advances in treatment and optimization of chemotherapy protocols have greatly improved survival in cancer patients. Unfortunately, treatment can cause a reduction in left ventricular (LV) ejection fraction (EF) leading to cancer therapy-related cardiac dysfunction (CTRCD). We conducted a scoping review of published literature in order to identify and summarize the reported prevalence of cardiotoxicity evaluated by noninvasive imaging procedures in a wide-ranging of patients referred to cancer treatment as chemotherapy and/or radiation therapy.
METHODS
Different databases were checked (PubMed, Embase, and Web of Science) to identify studies published from January 2000 to June 2021. Articles were included if they reported data on LVEF evaluation in oncological patients treated with chemotherapeutic agents and/or radiotherapy, measured by echocardiography and/or nuclear or cardiac magnetic resonance imaging test, providing criteria of CTRCD evaluation such as the specific threshold for LVEF decrease.
RESULTS
From 963 citations identified, 46 articles, comprising 6841 patients, met the criteria for the inclusion in the scoping review. The summary prevalence of CTRCD as assessed by imaging procedures in the studies reviewed was 17% (95% confidence interval, 14-20).
CONCLUSIONS
The results of our scoping review endorse the recommendations regarding imaging modalities to ensure identification of cardiotoxicity in patients undergoing cancer therapies. However, to improve patient management, more homogeneous CTRCD evaluation studies are required, reporting a detailed clinical assessment of the patient before, during and after treatment.
Identifiants
pubmed: 36999824
doi: 10.1002/cam4.5854
pmc: PMC10242861
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
11396-11407Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Echocardiography. 2020 Mar;37(3):421-428
pubmed: 32112477
Ann Oncol. 2020 Feb;31(2):171-190
pubmed: 31959335
Clin Res Cardiol. 2020 Jun;109(6):673-684
pubmed: 31559482
JACC Cardiovasc Imaging. 2016 Oct;9(10):1131-1141
pubmed: 27085442
Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603
pubmed: 22744937
N Engl J Med. 2000 Apr 13;342(15):1077-84
pubmed: 10760308
J Nucl Cardiol. 2016 Aug;23(4):824-32
pubmed: 26048264
Breast Cancer Res Treat. 2011 Dec;130(3):845-54
pubmed: 21918836
Clin Res Cardiol. 2008 May;97(5):318-26
pubmed: 18193371
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Int J Cardiol. 2015 Jul 15;191:203-10
pubmed: 25974196
Arq Bras Cardiol. 2013 Apr;100(4):328-32
pubmed: 23525273
Circulation. 2015 Jun 2;131(22):1981-8
pubmed: 25948538
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Cancer Treat Rep. 1978 Jun;62(6):857-64
pubmed: 667859
Int J Health Policy Manag. 2014 Aug 13;3(3):123-8
pubmed: 25197676
Cardiovasc Hematol Disord Drug Targets. 2020;20(1):74-83
pubmed: 31513000
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Ann Oncol. 2003 Feb;14(2):277-81
pubmed: 12562656
Br J Cancer. 2002 Jun 5;86(11):1697-700
pubmed: 12087452
J Oncol. 2020 Nov 30;2020:5706561
pubmed: 33335549
J Am Heart Assoc. 2020 Jan 21;9(2):e015400
pubmed: 31959033
Circ Cardiovasc Imaging. 2021 Jun;14(6):e012459
pubmed: 34126756
Am J Cardiol. 2017 May 15;119(10):1637-1642
pubmed: 28341361
Med Oncol. 2017 Dec 22;35(1):14
pubmed: 29274027
Nucl Med Commun. 2011 May;32(5):381-5
pubmed: 21346663
Clin Cardiol. 2018 Mar;41(3):349-353
pubmed: 29569424
J Am Coll Cardiol. 2010 Nov 9;56(20):1644-50
pubmed: 21050974
J Am Coll Cardiol. 2011 May 31;57(22):2263-70
pubmed: 21616287
Eur J Heart Fail. 2019 Apr;21(4):529-535
pubmed: 30811091
J Nucl Cardiol. 2017 Jun;24(3):906-935
pubmed: 27225513
J Cardiovasc Magn Reson. 2017 Apr 10;19(1):44
pubmed: 28395671
Support Care Cancer. 2016 Jul;24(7):3139-45
pubmed: 26923461
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Heart Fail Rev. 2015 Sep;20(5):621-31
pubmed: 26168714
Eur Heart J. 2022 Jan 31;43(4):280-299
pubmed: 34904661
Biomed Res Int. 2020 Nov 12;2020:1847159
pubmed: 33274195
Eur J Heart Fail. 2020 Sep;22(9):1504-1524
pubmed: 32621569
Onkologie. 2013;36(12):712-6
pubmed: 24356562
Echocardiography. 2016 Aug;33(8):1166-77
pubmed: 27109429
Echocardiography. 2017 Nov;34(11):1593-1600
pubmed: 28942608
Expert Rev Mol Diagn. 2017 Mar;17(3):245-256
pubmed: 28092472
Breast Cancer Res Treat. 2007 Sep;104(3):341-9
pubmed: 17051423
Cancer Med. 2023 May;12(10):11396-11407
pubmed: 36999824
BMC Cancer. 2020 Jun 30;20(1):609
pubmed: 32605637
Eur Heart J Cardiovasc Imaging. 2021 Mar 22;22(4):406-415
pubmed: 33432333
Eur J Heart Fail. 2014 Mar;16(3):300-8
pubmed: 24464946
Clin Res Cardiol. 2020 Feb;109(2):255-262
pubmed: 31214777
Eur J Heart Fail. 2007 Apr;9(4):409-14
pubmed: 17067854
Ultrasound Med Biol. 2016 Jan;42(1):125-32
pubmed: 26603736
J Clin Oncol. 2002 Mar 1;20(5):1215-21
pubmed: 11870163
J Am Soc Echocardiogr. 2019 Apr;32(4):521-528
pubmed: 30826225
J Am Soc Echocardiogr. 2014 Sep;27(9):911-39
pubmed: 25172399
Eur Heart J. 2012 Jan;33(2):151-2
pubmed: 22351966
Breast Cancer Res Treat. 2016 Dec;160(3):491-499
pubmed: 27744486
Breast Cancer Res Treat. 2009 Sep;117(2):357-64
pubmed: 19082707
J Am Soc Echocardiogr. 2014 Jan;27(1):83-92
pubmed: 24268372
J Am Heart Assoc. 2018 Aug 7;7(15):e008637
pubmed: 30371238
Eur Heart J Cardiovasc Imaging. 2014 Mar;15(3):324-31
pubmed: 24057661
Eur J Echocardiogr. 2011 Dec;12(12):945-52
pubmed: 21965152
J Am Soc Echocardiogr. 2015 May;28(5):509-14
pubmed: 25772019
Eur Heart J. 2022 Nov 1;43(41):4229-4361
pubmed: 36017568
Breast Cancer (Dove Med Press). 2018 Dec 27;11:29-42
pubmed: 30643452
Nucl Med Commun. 2019 Jan;40(1):22-29
pubmed: 30418380